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Summary Loiasis, caused by the ﬁlarial parasite Loa loa, is endemic in West and Central
Africa. Ivermectin has been shown to be an effective treatment of loiasis. We report the case
of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and
developed severe hepatitis, identiﬁed 1 month after a single dose of ivermectin. Liver biopsy
showed intralobular inﬂammatory inﬁltrates, conﬂuent necrosis and apoptosis, compatible with
drug-induced liver disease. To our knowledge, this is the ﬁrst case of ivermectin-induced severe
liver disease published in the literature.
© 2006 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights
reserved.
1. Case report
In October 2000, a 20-year-old woman was referred to the
Swiss Tropical Institute, Basle, Switzerland, for evaluation of
amigrating worm in the sclera of her right eye (Figure 1). She
reported general body itching over several years, headache
and dizziness. She had lived in Cameroon until the age of 15;
she had moved to Switzerland 5 years previously and had
not visited Africa since then. She had had meningitis with
subsequent persistent deafness and a history of hepatitis A
and B. Initial physical examination was inconspicuous except
for moderate abdominal pain.
The worm that was removed from the patient’s right
eye was identiﬁed as an adult Loa loa, with a length of
2 cm. Initial L. loa microﬁlaraemia was 820/ml of whole
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blood. There was an eosinophilia of 18.5% (absolute count
350/l), and liver enzymes were normal. The patient was
treated with albendazole (600mg/d) for 21 d. One month
after the end of therapy, the microﬁlaraemia dropped to
250/ml and was still at this level 3 months thereafter
(Table 1). Clinical signs and liver enzymes remained nor-
mal, and no abdominal pain was reported. A single dose of
15mg (300g/kg) ivermectin, a dosage previously reported
as having no major side effects (Kombila et al., 1998),
was given to reduce the microﬁlaraemia further. At a rou-
tine follow-up 1 month after administration of ivermectin,
the patient reported moderate new diffuse abdominal pain.
Physical examination showed a new tenderness in the upper
right quadrant; the liver was not enlarged. Laboratory inves-
tigation revealed elevated liver enzymes: ALAT 907 IU/l
(normal range 7—42), ASAT 279 IU/l (normal range 5—39) and
GT 66 IU/l (normal range 8—78); bilirubin, alkaline phos-
phatase, C-reactive protein, and red and white blood cell
counts were in the normal range. Viral hepatitides were
ruled out by means of serology (HAV, HBV, HCV, CMV, EBV).
An HIV test was also negative. The patient had no his-
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Figure 1 Transocular migration of the Loa loa macroﬁlariae
(2 cm) in the patient.
Figure 2 Liver biopsy with intralobular inﬂammatory inﬁl-
trates, focal ceroid loaded macrophages, perivenular conﬂuent
necrosis and intralobular apoptosis.
tory of alcohol or drug abuse. No other medications had
been taken. A liver biopsy was performed, which showed
predominantly perivenular intralobular inﬂammatory inﬁl-
trates, with conglomeration of ceroid loaded macrophages
Figure 3 Follow-up of liver enzyme ALAT.
and conﬂuent necrosis and apoptosis (Figure 2). The biopsy
ﬁndings were consistent with resolving acute drug-induced
hepatitis.
The patient became asymptomatic after a few days. Four
months after the onset of hepatitis, all liver enzymes had
returned to normal values (Table 1 and Figure 3). As micro-
ﬁlaraemia still persisted (19mf/ml), diethylcarbamazine
(DEC) was given for 29 d (total 7293.75mg) and was well tol-
erated without any elevation of the liver enzymes. One week
after initiating DEC treatment and in all subsequent exami-
nations no microﬁlariae could be detected in the peripheral
blood and no clinical sign of loiasis appeared.
2. Discussion
The ﬁlarial parasite L. loa is endemic in West and
Central Africa, with an estimated 13 million people infected
(Toure et al., 1998). Typical manifestations are transocu-
lar migration or subcutaneous swelling (‘Calabar swelling’),
caused by migrating adult nematodes (macroﬁlariae). Other
common symptoms are generalized pruritus, fatigue and
arthralgias. Hepatic dysfunction has not been reported. In
exceptional cases, complications such as endomyocardial
ﬁbrosis and renal complications arise.
Diethylcarbamazine is the standard treatment of loia-
sis but is associated with an elevated risk of encephalitis
in patients with high microﬁlaraemia (Carme et al., 1991).
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Table 1 Laboratory ﬁndings
Date
5/10/00 27/12/00
Haemoglobin (g/dl) 11.8 13.6
Leucocytes (10× 3/l) 12.7 7.0
Eosinophilia (%) 18.5 9.5
ALAT [7—42 IU/l] 21 35
ASAT [5—39 IU/l] 23 23
GT [66—93 IU/l] 22 42
Alkaline phosphatase [38—126 IU/l] 58 40
Bilirubin [2—24mol/l] 11 8
Microﬁlaraemia (Loa loa) (/ml) 820 220vermectin is used for treatment in many diseases, includ-
ng loiasis, scabies, onchocerciasis and strongyloidiasis. In
he treatment of onchocerciasis with ivermectin, where L.
oa is endemic, encephalitis has been reported (Boussinesq
t al., 1998; Ducorps et al., 1995; Gardon et al., 1997).
20/2/01 26/03/01 23/04/01 13/7/01 23/7/01
13.2 12.5 12.4 12.1
8.0 10.5 8.7 9.5
14.0 6.6 4.5 6.5
907 111 54 23 13
279 47 27 20 5
66 27 27
61 57 43 46 38
22 16 20 21 13
9 19 0
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In our patient the results of the liver biopsy were com-
patible with drug-induced hepatotoxicity. At the time of
the diagnosis of drug-induced liver disease, the patient had
received two drugs in the previous 5 months: albendazole
and ivermectin. Albendazole, which has good effect against
L. loa microﬁlariae, was initially chosen over standard ther-
apy with DEC because of the mentioned elevated risk of
encephalitis in patients with high microﬁlaraemia. Alben-
dazole can produce hepatotoxicity, but in most cases this is
associated with the treatment of echinococcosis, in which
elevations of enzymes occur as the cysts are destroyed
(Horton, 1989). There are a few cases of drug-induced hep-
atitis in the literature (Morris and Smith, 1987). In our
case, the interval of several months between treatment with
albendazole and onset of symptoms, as well as the normal
liver enzymes following this treatment, are reasons to think
that albendazole was not the cause of this event.
The shorter interval between administration of iver-
mectin and the onset of symptoms, liver histology compat-
ible with hepatocellular toxicity, and no history of other
agents causing hepatitis all point to ivermectin as causative
agent of the drug-induced liver disease in our patient.
Idiosyncratic drug-induced liver disease occurs in 1—10 in
10 000 patients taking a speciﬁc medicine. A review of
published literature has not revealed any cases of severe
ivermectin-induced liver disease, not even in escalating high
doses of ivermectin (Guzzo et al., 2002). However, tran-
sient mild to moderate elevation of liver enzymes has been
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Zdescribed (Biour et al., 2004; Zaha et al., 2002). Ivermectin
is used for mass treatment against onchocerciasis, and also
in L. loa endemic regions. However, a case like ours prob-
ably would not have been recognized in an area in Central
Africa, where liver function tests are not routinely carried
out, especially in the absence of jaundice. Furthermore, in
a place where viral hepatitis is common, suspicion of drug-
induced hepatitis would be rather low. Therefore, in the
absence of controlled large clinical trials there is the poten-
tial to miss such variants of hepatitis.
3. Conclusion
We consider ivermectin to be the cause of drug-induced
hepatitis in our patient. To our knowledge, this is the ﬁrst
case of ivermectin-induced severe liver disease published
in the literature. In patients suffering from abdominal pain
after treatment with ivermectin, liver cell damage should
be considered.
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